SCHEMBL5120761

SCHEMBL5120761

CCc1cccc(CN(C[C@@H](O)[C@@H](N)Cc2cc(F)cc(F)c2)C(=O)CC(=O)Nc2ccc(Cl)c(Cl)c2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
CYP3A4 P08684 2/20 0.38
SPPL2A Q8TCT8 1/20 0.37
BACE1 P56817 3/20 0.36
CTSD P07339 2/20 0.36
DHODH Q02127 1/20 0.36
OPRL1 P41146 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
CETP P11597 1/20 0.35
HTT P42858 2/20 0.35
LMNA P02545 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
MAPT P10636 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
GAA P10253 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5126595 0.88 LMNA (0.41) MEN1KMT2ABACE1CTSDSMN1; SMN2
SCHEMBL14131279 0.83 BACE1 (0.39) SPPL2ABACE1CTSDLMNAMAPT
SCHEMBL5130327 0.83 BACE1 (0.40) BACE1CTSDSMN1; SMN2LMNAMAPT
SCHEMBL5120573 0.83 BACE1 (0.40) SPPL2ABACE1CTSD
SCHEMBL5120921 0.81 HTT (0.42) ALDH1A1MEN1KMT2ABACE1CTSD
SCHEMBL5579835 0.80 PPARA (0.38) ALDH1A1MEN1KMT2ABACE1CTSD
SCHEMBL5125902 0.80 KMT2A (0.41) ALDH1A1MEN1KMT2ACYP3A4BACE1
SCHEMBL5130825 0.79 BACE1 (0.45) BACE1CTSDSMN1; SMN2
SCHEMBL5579820 0.78 BACE1 (0.41) MEN1KMT2ABACE1CTSD
SCHEMBL5125285 0.78 BACE1 (0.37) MEN1KMT2ABACE1CTSDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 US disclosed
US-7294642-B2 1,3-Diamino-2-hydroxypropane pro-drug derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 ALDH1A1 2178/4885MEN1 1613/4885KMT2A 2573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.